[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616292":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":17,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":53,"collaborators":17,"id":55,"slug":17,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":17,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":17,"enrollmentInfo":63,"targetDuration":17,"studyType":66,"phases":17,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":39,"whyStopped":17,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Palo Alto Veterans Institute for Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"Circulating Tumor Cell (CTC)","blood samples","Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment",{"measure":14,"description":15,"timeFrame":16},"CTA imaging","imaging of liver tumor","Baseline, 3 months post treatment, 6 months post treatment",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Study Aims and Objectives:\n\n1. Assess the detection rate of CTC and cfDNA-based mutations and the distribution of molecular features of HCC prior to Y90 across BCLC A-C stages.\n2. Determine CTC and cfDNA predictors at baseline that predict Y90 treatment response at 6-9 months.\n3. Determine temporal changes in CTC and cfDNA mutations from baseline over 6-9 month course post Y90.\n4. Determine if CTC mean distribution, sCTCDNA, and\u002For cfDNA mutational dynamic changes are predictive of treatment response at 6-9 months.\n5. Assess radiomic and liquid biopsy signatures associated with outcome\n6. Compare predictive outcome models using liquid biopsy data, imaging data, or a combination (multiomic data)","Patients at VAPAHCS with HCC",[24],{"name":25,"affiliation":26,"role":27},"Sirish Kishore, MD","VA Palo Alto Health Care System","PRINCIPAL_INVESTIGATOR",[29,34],{"name":25,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","650-493-5000","61706","sirish.kishore@va.gov",{"name":35,"role":30,"phone":31,"phoneExt":32,"email":36},"Luisa Manfredi, MPH","luisa.manfredi1@va.gov",[38],{"facility":26,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Palo Alto","California","94304","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-122.14302,37.44188,{"lat":49,"lon":48},[52],{"name":25,"role":30,"phone":31,"phoneExt":32,"email":17},{"type":54,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100616292",false,"NCT07303712","Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90","Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization and Assessment of Treatment Response After Y90 Radioembolization: A Pilot Study","Inclusion Criteria:\n\n1. Age \\> or = 18 years\n2. HCC confirmed on imaging, BCLC stage 0, A, B, or C\n3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -\n\nExclusion Criteria:\n\n1. Not eligible for Y90 procedure\n2. Prior surgery or ablation on indicated tumors\n3. Patient unable to complete the follow up visits required for clinical care or research -","ALL","18 Years",{"count":64,"type":65},12,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).",[69],"Hepatocellular Carcinoma (HCC)",[71,72],"Circulating tumor cell (CTC)","y90","2025-12-18",{"date":75,"type":76},"2025-12-26","ACTUAL",{"date":78,"type":76},"2024-08-01",{"date":80,"type":65},"2026-12-01",{"name":5,"class":6},1]